Apixaban is a medication used to prevent blood clots. It works by blocking certain proteins in your blood that are involved in clotting. In this trial, it is being tested for its safety and effectiveness in patients with non-valvular atrial fibrillation who are undergoing peritoneal dialysis.

Warfarin is another medication that helps prevent blood clots. It works by decreasing the clotting ability of the blood. This trial is comparing warfarin to apixaban to see which is safer and more effective for patients with non-valvular atrial fibrillation on peritoneal dialysis, particularly focusing on the risk of bleeding.

End-Stage Renal Disease – This is the final stage of chronic kidney disease where the kidneys can no longer function adequately to meet the body’s needs. Patients often require dialysis or a kidney transplant to survive. The disease progresses as kidney function declines over time, leading to the accumulation of waste products and fluid in the body. Symptoms may include fatigue, swelling, and difficulty concentrating. It is often associated with other health issues such as high blood pressure and anemia. Management focuses on slowing progression and addressing complications.

Non-Valvular Atrial Fibrillation – This is a type of irregular heartbeat that is not caused by a heart valve issue. It occurs when the heart’s upper chambers beat out of sync with the lower chambers, leading to poor blood flow. The condition can cause symptoms like palpitations, shortness of breath, and fatigue. It may increase the risk of stroke and other heart-related complications. The progression can vary, with some individuals experiencing occasional episodes and others having persistent symptoms. Management typically involves controlling the heart rate and reducing the risk of stroke.